Abstract
Background Thrombosis with thrombocytopenia syndrome (TTS) is a potentially life-threatening condition associated with adenoviral-vectored COVID-19 vaccination. TTS presents similarly to autoimmune heparin-induced thrombocytopenia. Twelve cases of cerebral venous sinus thrombosis following Janssen/Johnson & Johnson (Ad26.COV2.S) COVID-19 vaccination have been described.
Objective Describe surveillance data and reporting rates of TTS cases following COVID-19 vaccination.
Design Case series.
Setting United States
Patients Case-patients reported to the Vaccine Adverse Event Reporting System (VAERS) receiving COVID-19 vaccine from December 14, 2020 through August 31, 2021, with thrombocytopenia and thrombosis (excluding isolated ischemic stroke or myocardial infarction). If thrombosis was only in an extremity vein or pulmonary embolism, a positive enzyme-linked immunosorbent assay for anti-platelet factor 4 antibody was required.
Measurements Reporting rates (cases/million vaccine doses) and descriptive epidemiology.
Results 52 TTS cases were confirmed following Ad26.COV2.S (n=50) or mRNA-based COVID-19 (n=2) vaccination. TTS reporting rates were 3.55 per million (Ad26.COV2.S) and 0.0057 per million (mRNA-based COVID-19 vaccines). Median age of patients with TTS following Ad26.COV2.S vaccination was 43.5 years (range: 18–70); 70% were female. Both TTS cases following mRNA-based COVID-19 vaccination occurred in males aged >50 years. All cases following Ad26.COV2.S vaccination involved hospitalization including 32 (64%) with intensive care unit admission. Outcomes of hospitalizations following Ad26.COV2.S vaccination included death (12%), discharge to post-acute care (16%), and discharge home (72%).
Limitations Under-reporting and incomplete case follow-up.
Conclusion TTS is a rare but serious adverse event associated with Ad26.COV2.S vaccination. The different demographic characteristics of the two cases reported after mRNA-based COVID-19 vaccines and the much lower reporting rate suggest that these cases represent a background rate.
Funding Source CDC
Competing Interest Statement
Dr. Streiff reported receiving grants from Janssen for the Cassini clinical trial of rivaroxaban for prevention of cancer-associated thrombosis. He reported receiving personal fees from Janssen for serving on the advisory board for the Cassini trial; from Bayer, BristolMyersSquib and Dispersol for providing consultative advice; from Bayer for CME lectures; and from Pfizer for CME lectures and serving on their advisory board. Dr. Streiff reported receiving grants from the NIH-NHLBI for his study on missed doses in VTE prophylaxis, from AHRQ for his work on individualized feedback on VTE prophylaxis practices and from PCORI for his research on patient education to improve acceptance of VTE prophylaxis. Dr. Edwards has grant funding from NIH and CDC; has worked as a consultant to Bionet and IBM; and has been a member of the Data Safety and Monitoring Board for Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, and Roche. Dr. Talaat reported receiving grants from Pfizer for serving as the site principal investigator for the Phase 3 adult COVID-19 vaccine study and the Phase 1-3 pediatric (under 12) COVID-19 vaccine study, both at Johns Hopkins University. She also reported receiving grants for serving as an investigator on the NIH (COVPN) AstraZeneca COVID-19 vaccine trial in adults. Dr. Walter is a principal investigator for Pfizer-funded studies of COVID-19 vaccine (Adults and Children) and an NIH-funded study of the AstraZeneca COVID-19 vaccine (Adults), a co-investigator for a vaccine study funded by Moderna, and a member of an advisory board for Vaxcyte. Dr. Ortel has received research support from Instrumentation Laboratory, Stago, and Siemens, related to laboratory analysis of coagulation disorders, and from the Centers for Disease Control and Prevention, related to surveillance for venous thromboembolism. Dr. Ortel has also provided consultative services to Instrumentation Laboratory for compensation. Dr. Ortel has also received honoraria for contributions to UpToDate on the diagnosis and management of antiphospholipid syndrome.
Funding Statement
This work was supported by the Centers for Disease Control and Prevention Clinical Immunization Safety Assessment (CISA] project contracts 200-2012-53664-0005 to Johns Hopkins University, 200-2012-50430-0005 to Vanderbilt University Medical Center, 200-2012-53663-0011 to Duke University, and 200-2012-53665-0005 to Columbia University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human subjects advisors of Centers for Disease Control and Prevention gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to legal restrictions related to confidentiality, the original data are not available to the public.
